Secondary osteoporosis: Pathophysiology & diagnosis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 6, 2014, Pages 911-935

  Emkey, Gregory R ^a   Epstein, Sol ^b  

^a Pennsylvania Regional Center for Arthritis and Osteoporosis Research   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase inhibitors; Fragility fractures; Glucocorticoids; Hypercalciuria; Hyperparathyroidism; Hyperthyroidism; Multiple myeloma; Osteoporosis; Secondary osteoporosis; Vitamin D deficiency

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; AROMATASE INHIBITOR; GLUCOCORTICOID; HEPARIN; MEDROXYPROGESTERONE ACETATE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ACROMEGALY; ANKYLOSING SPONDYLITIS; ANOREXIA NERVOSA; ARTICLE; BARIATRIC SURGERY; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; FRACTURE; FRAGILITY FRACTURE; HUMAN; HYPERTHYROIDISM; HYPOGONADISM; INFLAMMATORY BOWEL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; OSTEOLYSIS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIMARY HYPERPARATHYROIDISM; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SECONDARY OSTEOPOROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC MASTOCYTOSIS; THALASSEMIA MAJOR; VITAMIN D DEFICIENCY; CHEMICALLY INDUCED; OSTEOPOROSIS;

HUMANS; OSTEOPOROSIS;

EID: 84924697056     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.07.002     Document Type: Review

References (259)

1. Weinstein RS. Clinical practice: Glucocorticoid-induced bone disease. N Engl J Med 2011; 364: 44-52.
2. Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006; 17: 105-8.
3. Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28.
4. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004; 15: 323-8.
5. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone 2006; 39: 253-9.
6. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteoclasts by glucocorticoids. Potential mechanism of their deleterious effects on bone. J Clin Invest 1998; 102: 274-82.
7. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-41.
8. Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Rev Commun 2005; 329: 177-81.
9. Gifre L, Ruiz-Gaspa S, Monegal A, et al. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 2013; 57: 272-6.
10. Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010; 9: 147-61.
11. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-9.
12. Humphrey EL, Williams JH, Davie MW, et al. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006; 38: 652-61.
13. Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their lifespan and reduce bone density. Endocrinology 2006; 147: 5592-9.
14. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Min 1990; 8: 39-51.
15. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9.
16. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin Am 2012; 41: 595-611.
17. Bilezikian JP, Khan AA, Potts Jr. JT. Third international workshop on the management asymptomatic hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 335-9.
18. Khan A, Bilezikian J. Primary hyperparathyroidism: Pathophysiology and impact on bone. CMAJ 2000; 163: 184-7.
19. Roschger P, Dempster DW, Zhou H, et al. New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res 2007; 22: 717-23.
20. Zoehrer R, Dempster DW, Bilezikian JP, et al. Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2008; 93: 3484-9.
21. Szymczak J, Bohdanowicz-Pawlak A. Osteoprotegerin, RANKL, and bone-turnover in primary hyperparathyroidism: The effect of parathyroidectomy and treatment with alendronate. Horm Metab Res 2013; 45: 759-64.
22. Kaji H, Imanishi Y, Sugimoto T, et al. Comparisons of serum sclerostin levels among patients with postmenopausal osteoprosis, primary hyperparathyroidism, and osteomalacia. Exp Clin Endocrinol Diabetes 2011; 119: 440-4.
23. Viapiana O, Fracassi E, Troplini S, et al. Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 2013; 92: 324-9.
24. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk: A meta-analysis. Thyroid 2003; 13: 585-93.
25. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4: 319-26.
26. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999; 130: 750-8.
27. Svare A, Nilsen TI, Bjoro T, et al. Hyperthyroid levels of TSH correlate with low bone mineral density: The HUNT 2 study. Eur J Endocrinol 2009; 161: 779-86.
28. Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low thyroid-stimulating hormone. Ann Intern Med 2001; 134: 561-8.
29. Abe E, Marians RC, Yu W, et al. Cell 2003; 115: 151-62.
30. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18: 988-1028.
31. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008; 29: 535-59.
32. Andreassen TT, Oxlund H. The effects of growth hormone on cortical and cancellous bone. J Musculoskelet Neuronal Interact 2001; 2: 49-58.
33. De Jesus K, Wang X, Liu JL. A general IGF-1 overexpression effectively rescued somatic growth and bone deficiency in mice caused by growth hormone receptor knockout. Growth Factors 2009; 27: 438-47.
34. Bravenboer N, Holzmann P, de Boer H, et al. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 1996; 18: 551-7.
35. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001; 16: 398-405.
36. Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-1 are significant determinants of bone turnover but not bone mineral density in active acromegaly: A prospective study of more than 70 consecutive patients. Eur J Endocrinol 2006; 155: 709-15.
37. Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 1997; 7: 226-30.
38. Scillitani A, Battista C, Chiodini I, et al. Bone mineral density in acromegaly: The effect of gender, disease activity and gonadal status. Clin Endocrinol 2003; 58: 725-31.
39. Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: A 3-year prospective study. J Clin Endocrinol Metab 2013; 98: 3402-10.
40. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women. J Bone Miner Res 2005; 20: 1837-44.
41. Clarke BL, Khosla S. Androgens and bone. Steroids 2009; 74: 296-305.
42. Mohr BA, Guay AT, O'Donnell AB, et al. Normal, bound, and nonbound testosterone levels in normal aging men: Results from the Massachusetts male aging study. Clin Endocrinol 2005; 62: 64-73.
43. Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention, and management. Drugs Aging 1998; 13: 421-34.
44. Kasperk CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576-8.
45. Casperk CH, Wakley GK, Hierl T, et al. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 1997; 12: 464-71.
46. Riggs BL, Khosla S, Melton III LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
47. Leder BZ, LeBlanc KM, Schoenfeld DA, et al. Differential effect of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88: 204-10.
48. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-74.
49. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000; 19: 951-63.
50. Travison TG, Araujo AB, Beck TJ, et al. Relation between serum testosterone, serum estradiol, sex-hormone binding globulin, and geometric measures of adult male proximal femur strength. J Clin Endocrinol Metab 2009; 94: 853-60.
51. LeBlanc ES, Nielson CM, Marshall LM, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin on fracture risk in older men. J Clin Endocrinol Metab 2009; 94: 3337-46.
52. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85: 219-23.
53. Inzerillo AM, Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 2004; 5: 261-8.
54. Epstein S, Leroith D. Diabetes and fragility fractures - A burgeoning epidemic? Bone 2008; 43: 3-6.
55. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192-7.
56. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: TheWomen's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-10.
57. Pan H, Wu N, Yang T, et al. Association between bone mineral density and type 1 diabetes mellitus: A meta-analysis of cross-sectional studies. Diabetes Metab Res Rev 2013; Dec 16 [Epub ahead of print].
58. Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: A meta-analysis of observational studies. Eur J Epidemiol 2012; 27: 319-32.
59. Burghardt AJ, Issever AS, Schwartz AV, et al. High resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 5045-55.
60. Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014; 29: 787-95.
61. Bouillon R, Bex M, Van Herck E, et al. Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 1995; 80: 1190-202.
62. Kemink SA, Hermus AR, Swinkels LM, et al. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 2000; 23: 295-303.
63. Fowlkes JL, Bunn RC, Thrailkill KM. Contributions of the insulin/insulin-like growth factor-1 axis to diabetic osteopathy. J Diabetes Metab 2011; 1: S1-003.
64. Hie M, Litsuka N, Otsuka T, et al. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Mol Med 2011; 28: 455-62.
65. Khosravi R, Sodek KL, Faibish M, et al. Collagen advanced glycation inhibitis its discoidin domain receptor 2-mediated induction of lysyl oxidase in osteoblasts. Bone 2014; 58: 33-41.
66. Rosen CJ, Bouxsein ML. Mechanisms of disease: Is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006; 2: 35-43.
67. Kawai M, Rosen CJ. PPARg: A circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010; 6: 629-36.
68. de Liefde II , van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: The Rotterdam Study. Osteoporos Int 2005; 16: 1713-20.
69. Sai AJ, Walters RW, Fang X, et al. Relationship between vitamin D, parathyroid hormone, and bone health. J Clin Endocrinol Metab 2011; 96: E436-46.
70. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004; 80: 1706Se9S.
71. Amling M, Priemel M, Holzmann T, et al. Rescue of skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biochemical analyses. Endocrinology 1999; 140: 4982-7.
72. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Positive association between 25-hydroxy vitamin D levels and bone mineral density; a population-based study of younger and older adults. Am J Med 2004; 1: 634-9.
73. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoprosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212-21.
74. Cauley JA, Lacroix AZ, Horwitz M, et al. Serum 25-hydroxyvitamin D concentration and risk for hip fractures. Ann Intern Med 2008; 149: 242-50.
75. Cauley JA, Parimi M, Ensrud KA, et al. Serum 25-hydroxyvitamin D and the risk of hip and non-spine fractures in older men. J Bone Miner Res 2010; 25: 545-53.
76. Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 2008; 23: 143-50.
77. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Am J Clin Nutr 2004; 80: 752-8.
78. Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 111-3.
79. Bultink E. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 2012; 64: 2-8.
80. Land NE. Vitamin D and systemic lupus erythematosus: Bones, muscles, and joints. Curr Rheumatol Rep 2010; 12: 259-63.
81. Tang XL, Griffith JF, Qin L, et al. SLE disease per se contributes to deterioration in bone mineral density, microstructure, and bone strength. Lupus 2013; 22: 1162-8.
82. Walsh NC, Crotti TN, Goldring SR, et al. Rheumatic diseases: The effects of inflammation on bone. Immunol Rev 2005; 208: 228-51.
83. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: Comparison with United States population data. Arthritis Rheum 1999; 42: 882-90.
84. Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 2007; 34: 2018-23.
85. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: Relation between disease severity and low bone mineral density. Ann Rheum Dis 2004; 63: 1576-80.
86. Solomon DH, Finkelstein JS, Shadick N, et al. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with osteoporosis. Arthritis Rheum 2009; 60: 1624-31.
87. Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications. Arthritis Res 2000; 2: 33-7.
88. Geusens PP, Landewe RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772-7.
89. van Tuyl LH, Voskuyl AE, Boers M, et al. Baseline RANKL: OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1623-8.
90. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin, and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495-9.
91. Terpos E, Fragiadaki K, Konsta M, et al. Early effects of IL-6 receptor inhibition on bone homeostasis: A pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 921-5.
92. Ghozlani I, Ghazi M, Nouijai A, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009; 44: 772-6.
93. van der Weijdan MA, Claushuis TA, Nazari T, et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: A systematic review. Clin Rheumatol 2012; 31: 1529-35.
94. Mitra D, Elvins DM, Speden DJ, et al. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 2000; 39: 85-9.
95. Kwon SR, Lim MJ, Suh CH, et al. Dickkopf-1level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis therapy. Rheumatol Int 2012; 32: 2523-7.
96. Korkosz M, Gasowski J, Leszczynski P, et al. Effect of tumour necrosis factor-A inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand J Rheumatol 2014; 43: 43-8.
97. Szollar SM, Martin EM, Sartoris DJ, et al. Bone mineral density and indexes of bone metabolism in spinal cord injury. Am J Phys Med Rehabil 1998; 77: 28-35.
98. Zehnder Y, Luthi M, Michel D, et al. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: A cross-sectional observational study in 100 paraplegic men. Osteoporos Int 2004; 15: 180-9.
99. Weinreb M, Rodan GA, Thompson DD. Osteopenia in the immobilized rat limb is associated with increased bone resorption and decreased bone formation. Bone 1989; 10: 187-94.
100. Chantraine A, Nusgens B, Lapiere CM. Bone remodeling during the development of osteoporosis in paraplegia. Calcif Tissue Int 1986; 38: 323-7.
101. Roberts D, Lee W, Cuneo RC, et al. Longitudinal study of bone turnover after acute spinal cord injury. J Clin Endocrinol Metab 1998; 83: 415-22.
102. Jiant SD, Yan J, Jiang LS, et al. Down-regulation of the Wnt, estrogen receptor, insulin-like growth factor-1, and bone morphogenetic protein pathways in osteoblasts from rats with chronic spinal cord injury. Jt Bone Spine 2011; 78: 488-92.
103. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-53.
104. Vico L, Collet P, Guignandon A, et al. Effects of long-term microgravity exposure on cancellous and cortical weightbearing bones of cosmonauts. Lancet 2000; 355: 1607-11.
105. Pickering RM, Grimbergen YA, Rigney U, et al. A meta-analysis of six prospective studies of falling in Parkinson's disease. Mov Disord 2007; 15: 1892-900.
106. Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson's disease. Age Ageing 2009; 38: 675-80.
107. Johnell O, Melton III LJ, Atkinson EJ, et al. Fracture risk in patients with parkinsonism: A population-based study in Olmstead County, Minnesota. Age Ageing 1992; 21: 32-8.
108. Invernizzi M, Carda S, Viscontini GS, et al. Osteoporosis in Parkinson's disease. Park Relat Disord 2009; 15: 339-46.
109. Vasserman N. Parkinson's disease and osteoporosis. Jt Bone Spine 2005; 72: 484-8.
110. Ozgocmen S, Bulut S, Ilhan N, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: Effect of ambulatory status and functional capacity. J Bone Min Metab 2005; 23: 309-13.
111. Weinstock-Guttman B, Gallagher E, Baier M, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004; 10: 170-5.
112. Ayatollahi A, Mohajeri-Tehrani MR, Nafissi S. Factors affecting bone mineral density in multiple sclerosis patients. Iran J Neurol 2013; 12: 19-22.
113. Dennison EM, Compston JE, Flahive J, , et alGLOWInvestigators. Effect of co-morbidities on fracture risk: Findings from Global Longitudinal Study of Osteoporosis in Women (GLOW) . Bone 2012; 50: 1288-93.
114. Nieves J, Cosman F, Herbert J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687-92.
115. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
116. Roodman JD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32: 290-2.
117. Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of Dkk-1 in IL-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986-91.
118. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: Focus on the receptor activator of NF-KappaB ligand. Exp Hematol 2004; 32: 685-91.
119. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671-5.
120. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells indue imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 15: 3527-33.
121. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma cells. Blood 2003; 101: 3568-73.
122. Zangari M, Yaccoby S, Pappas L, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haemotologica 2011; 96: 333-6.
123. Tian E, Zhan F, Walker R, et al. The role of Wnt-signaling antagonist DKK1in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-94.
124. Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting DKK1 removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009; 24: 425-36.
125. Bida JP, Kyle RA, Therneau TM, et al. Disease associations of monoclonal gammopathy of undetermined significance: A population-based study of 17,398 patients. Mayo Clin Proc 2009; 84: 685-93.
126. Melton 3rd LJ, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19: 25-30.
127. Ng AC, Khosla S, Charatcharoenwitthaya N, et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. Blood 2011; 118: 6529-34.
128. Politou M, Terpos E, Anagnostopoulos A, et al. Role of RANKL, osteoprotegerin, and macrophage protein 1-alpha in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 126: 686-9.
129. De Sanctis V, Soliman AT, Yassin M, et al. Osteoporosis in thalassemia major: An update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 2013; 11: 167-80.
130. Perisiano C, Marzetti E, Spinelli MS, et al. Pathophysiology of bone modifications in B-thalassemia. Anemia 2012; 2012: 5. Article ID 320737.
131. Mahachoklerwattana P, Sirikulchayanonta V, Chuansumrit A, et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: Iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003; 88: 3966-72.
132. Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 2012; 44: 909-13.
133. Morabito N, Russo GT, Gaudio A, et al. The "lively" cytokines network in beta-thalassemia major-related osteoporosis. Bone 2007; 40: 1588-94.
134. Rossini M, Zanotti R, Bonadonna P, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49: 880-5.
135. Brumsen C, Papapoulos SE, Lentjes EG, et al. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 2002; 31: 556-61.
136. Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006; 36: 32-6.
137. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128: 344-50.
138. Brown TT, Qagish RB. Antiretroviral therapy and the prevalence of osteopenia in osteoporosis: A meta-analytic review. Aids 2006; 20: 2165-74.
139. Guerri-Fernandez R, Vestergaard P, Carbonell P, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort study. J Bone Miner Res 2013; 28: 1259-63.
140. de Menezes Barbosa EG, de Paula FJ, Machado AA, et al. Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients. Bone 2013; 57: 62-7.
141. Yin MT, Kendall MA, Wu X, et al. AIDS 2012; 26: 2175-84.
142. Del Carpio-Cano FE, Dela Cadena RA, Sawaya BE. HIV and bone disease: A perspective of the role of microRNAs in bone biology upon HIV infection. J Osteoporos 2013: 571418.
143. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand secretion and its modulation by certain HIV protease inhibitors through interferongamma/RANKL cross-talk. J Biol Chem 2003; 278: 48251-8.
144. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of RANKL via potentiation of glucocorticoid receptor activity. Arch Virol 2005; 150: 67-78.
145. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42: 108-14.
146. Herbeuval JP, Boasso A, Grivel JC, et al. TNR-related apoptosis-inducing ligand in HIV-1 infected patients and its in vitro production by antigen-presenting cells. Blood 2005; 105: 2458-64.
147. Sakhaee K, Maalouf NM, Kumar R, et al. Nephrolithiasis-associated bone disease: Pathogenesis and treatment options. Kidney Int 2011; 79: 393-403.
148. Garcia-Nieto V, Navarro JF, Monge M, et al. Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract 2003; 94: C89-93.
149. Melton 3rd LJ, Crowson CS, Khosla S, et al. Fracture risk among patients with urolithiasis: A population-based cohort study. Kidney Int 1998; 53: 459-64.
150. Miller PD. Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012; 41: 613-28.
151. Aung K, Htay K. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev 2011; 10: CD005185.
152. Malluche HH, Tschoepe W, Ritz E, et al. Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980; 50: 654-8.
153. Heilberg IP, Weisinger JR. Bone disease in idiopathic hypercalciuria. Curr Opin Nephrol Hypertens 2006; 15: 394-402.
154. Pak CY, Odvina CV, Pearle MS, et al. Effect of dietary modification on urinary stone risk factors. Kidney Int 2005; 68: 2264-73.
155. Coe FL, Favus MJ, Crockett T, et al. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25 (OH) 2D3 levels in patients with idiopathic hypercalciura and in normal subjects. Am J Med 1982; 72: 25-32.
156. Favus MJ, Karnauskas AJ, Parks JH, et al. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89: 4937-43.
157. Frick KK, Asplin JR, Krieger NS, et al. 1,25 (OH) 2D3-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low calcium diet. Am J Physiol Renal Physiol 2013; 305: 1132-8.
158. Ng AH, Frick KK, Krieger NS, et al. 1,25 (OH) 2D3 induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats. Calcif Tissue Int 2014; 94: 531-43.
159. Bai S, Wang H, Shen J, et al. Elevated vitamin D receptor levels in genetic hypercalciuric stone-forming rats are associated with downregulation of Snail. J Bone Miner Res 2010; 25: 830-40.
160. Misra M, Aggarwal A, Miller KK, et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics 2004; 114: 1574-83.
161. Wiksten-Almstromer M, Hirschberg AL, Hagenfeldt K. Reduced bone mineral density in adult women diagnosed with menstrual disorders during adolescence. Acta Obstet Gynecol Scand 2009; 88: 543-9.
162. Faje AT, Karim L, Taylor A, et al. Adolescent girls with anorexia nervosa have impaired cortical and trabecular microarchitecture and lower estimated bone strength at the distal radius. J Clin Endocrinol Metab 2013; 98: 1923-9.
163. Faje AT, Fazell PK, Miller KK, et al. Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int J Eat Disord 2014; 47: 458-66.
164. Misra M, Klibanski A. Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes 2011; 18: 376-82.
165. Bredalla M, Fazeli PK, Miller KK, et al. Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab 2009; 94: 2129-36.
166. Stenson WF, Newberry R, Lorenz R, et al. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005; 165: 393-9.
167. Meyer D, Stavropoulos S, Diamond B, et al. Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol 2001; 96: 112-9.
168. Mazzure R, Vazquez H, Gonzalez D, et al. Bone mineral affection in asymptomatic adult patients with celiac disease. Am J Gastroenterol 1994; 89: 2130-4.
169. West J, Logan RF, Card TR, et al. Fracture risk in people with celiac disease: A population-based cohort study. Gastroenterology 2003; 125: 429-36.
170. Ludvigsson JF, Michaelsson K, Ekbom A, et al. Celiac disease and the risk of fractures - A general population-based cohort study. Ailment Pharmacol Ther 2007; 25: 273-85.
171. Walters JR, Banks LM, Butcher GP, et al. Detection of low bone mineral density by DEXA in unsuspected suboptimally treated coeliac disease. Gut 1995; 37: 220-4.
172. Keaveny AP, Freaney R, McKenna MJ, et al. Bone remodeling indices and secondary hyperparathyroidism in celiac disease. Am J Gastroenterol 1996; 91: 1226-31.
173. Chakravarthi SD, Jain K, Kochhar R, et al. Prevalence and predictors of abnormal bone mineral metabolism in recently diagnosed adult celiac patients. Indian J Gastroenterol 2012; 31: 165-70.
174. Valdimmarson T, Toss G, Lofman O, et al. Three years' follow-up of bone density in adult celiac disease: Significance of secondary hyperparathyroidism. Scand J Gastroenterol 2000; 35: 274-80.
175. Fornari MC, Pedreira S, Niveloni S, et al. Pre-and post-treatment serum levels of cytokines IL-1b, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to associated osteopenia? Am J Gastroenterol 1998; 93: 413-8.
176. Taranta A, Fortunati D, Longo M, et al. Imbalance of osteogenesis-regulating factors in patients with celiac disease. J Bone Miner Res 2004; 19: 1112-21.
177. Fiore CE, Pennisi P, Ferro G, et al. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with glute-free diet. Horm Metab Res 2006; 38: 417-22.
178. Frei P, Fried M, Hungerbuhler V, et al. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 2006; 73: 40-6.
179. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: A nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002; 156: 1-10.
180. Loftus Jr. EV, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: A populationbased study in Olmsted County, Minnesota. Gastroenterology 2002; 123: 468-75.
181. Bernstein CN, Blanchard JF, LeslieW, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-9.
182. Rodriguez-Bores L, Fonseca GC, Villeda MA, et al. Novel genetic markers in inflammatory bowel disease. World J Gastroenterol 2007; 13: 5560-70.
183. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1895-902.
184. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: Association with disease activity and quality of life. JPEN 2011; 35: 308-16.
185. Vernia P, Loizos P, Di Giuseppantonio I, et al. Dietary calcium intake in patients with inflammatory bowel disease. J Crohns Colitis 2014; 8: 312-7.
186. van Hogezand RA, Banffer D, Zwinderman AH, et al. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int 2006; 17: 535-42.
187. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54: 479-87.
188. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-14.
189. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 1605-11.
190. Vilarrasa N, Gomez JM, Elio I, et al. Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss. Obes Surg 2009; 19: 860-6.
191. Vilarrasa N, de Gordejuela AG, Gomez-Vaquero C, et al. Effect of bariatric surgery on bone mineral density: Comparison of gastric bypass and sleeve gastrectomy. Obes Surg 2013; 23: 2086-91.
192. Yu EW. Bone metabolism after bariatric surgery. J Bone Miner Res 2014; 29: 1507-18.
193. Sinha N, Shieh A, Stein EM, et al. Increased PTH and 1,25OH2D levels associated with increased markers of bone turnover following bariatric surgery. Obesity 2011; 19: 2388-93.
194. Carrasco F, Basfi-Fer K, Rojas P, et al. Changes in bone mineral density after sleeve gastrectomy or gastric bypass: Relationships with variations in vitamin D, ghrelin, and adiponectin levels. Obes Surg 2014; 24: 877-84.
195. Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res 2005; 20: 790-8.
196. XiaomeiW, Hang X, Lingling L, et al. Bone metabolism status and associated risk factors in elderly patients with COPD. Cell Biochem Biophys 2014-03-15: 1-6.
197. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-107.
198. Bon J, Furhman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011; 183: 885-90.
199. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286-93.
200. de Vries F, van Staa TP, Bracke MS, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25: 879-84.
201. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: A systematic review and metaanalysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699-708.
202. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
203. Romme EA, Rutten EP, Smeenk FW, et al. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Intern Med 2013; 45: 91-6.
204. Schlaich C, Minne HW, Bruckner T, et al. Reduced pulmonary function in patients with osteoporotic fractures. Osteoporos Int 1998; 8: 261-7.
205. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009; 94: 1483-90.
206. Epstein S, Inzerillo AM, Caminis J, et al. Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 2003; 18: 2083-94.
207. Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration. Endocrinology 1988; 123: 2571-7.
208. Kirino S, Fukunaga J, Ikegami S, et al. Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J Bone Miner Metab 2004; 22: 554-60.
209. Movsowitz C, Epstein S, Ismail F, et al. Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption. J Bone Miner Res 1989; 4: 393-8.
210. Chowdhury MH, Shen V, Dempster DW. Effects of cyclosporine A in chick osteoclasts in vitro. Calcif Tissue Int 1991; 49: 275-9.
211. Buchinsky FJ, Ma Y, Mann GN, et al. T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 1996; 137: 2278-85.
212. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med 1997; 103: 197-207.
213. Majumdar S, Ezekowitz JA, Lix LM, et al. Heart failure is a clinically and densitometrically independent and novel risk factor for major osteoporotic fractures: Population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab 2012; 97: 1179-86.
214. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescentsethe Black Box Warning: A position paper for the Society of Adolescent Medicine. J Adolesc Health 2006; 39: 296-301.
215. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303: 13-6.
216. Curtis KM, Martins SL. Progestin-only contraception and bone mineral density: A systematic review. Contraception 2006; 73: 470-87.
217. Clark MK, Sowers M, Levy B, et al. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2006; 86: 1466-74.
218. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008; 77: 67-76.
219. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrazole, Tamoxifen, Alone, or in Combination (ATAC) trial (18233230) . J Bone Miner Res 2006; 21: 1215-23.
220. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrazole on bone mineral density: 5-year results from the anastrazole, tamoxifen, alone, or in combination trial 18233230. J Clin Oncol 2008; 26: 1051-7.
221. ATAC Trialists' Group, Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrazole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
222. Bouvard B, Soulie P, Hoppe M, et al. Fracture incidence after 3 years of aromatase inhibitor therapy. Ann Oncol 2014; 25: 843-7.
223. Servitja S, Nogues X, Prieto-Alhambra D, et al. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast 2012; 21: 95-101.
224. Ali AA,Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146: 1226-35.
225. Beck Jr. GR, Khazai NB, Bouloux GF, et al. The effects of thiazolinediones on human bone marrow stromal cell differentiation in vitro and in thiazolinedione-treated patients with type 2 diabetes. Transl Res 2013; 161: 145-55.
226. Moldes M, Zuo Y, Morrison RF, et al. Peroxisome-proliferator-activator receptor gamma suppresses Wnt/beta-catenin signaling during adipogenesis. Biochem J 2003; 376: 607-13.
227. Lecka-Czarnik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activator gamma by roiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148: 903-11.
228. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT) . Diabetes Care 2008; 31: 845-51.
229. Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 134-42.
230. Loke YK, Singh S, Furgerg CD. Long term use of thiazolinediones and fracture in type 2 diabetes: A meta-analysis. CMAJ 2009; 180: 32-9.
231. Grisso JA, Kelsey JL, O'Brien LA, et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 1997; 145: 786-93.
232. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
233. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83.
234. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the Women's Health Initiative. Arch Intern Med 2010; 170: 765-71.
235. Yu EW, Blackewell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-9.
236. Graziani G, Como G, Badalamenti S, et al. Nephrol Dial Transpl 1995; 10: 1376-80.
237. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010; 25: 2786-95.
238. Heller HJ, Greer LG, Haynes SD, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol 2000; 40: 1237-44.
239. Farhat G, Yamout B, Mikate MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58: 1348-53.
240. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45: 1330-7.
241. Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010; 8: 34-46.
242. Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther Adv Musculoskelet Dis 2011; 3: 235-43.
243. Mikati MA, Dib L, Yamout B, et al. Fuleihan Gel-H. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: Impact on bone. Neurology 2006; 67: 2005-14.
244. Lee RH, Lyles KW, Sloane R, et al. The association of newer anticonvulsant medications and bone mineral density. Endocr Pract 2012; 14: 1-22.
245. Bliziotes MM, Eshelman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 2001; 29: 477-86.
246. Diem SJ, Harrison SL, Haney E, et al. Depressive symptoms and rates of bone loss at the hip in older men. Osteoporos Int 2013; 24: 111-9.
247. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167: 1246-51.
248. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167: 188-94.
249. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: The study of osteoporotic fractures. Arch Intern Med 2007; 167: 1240-5.
250. Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 2008; 23: 567-74.
251. Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005; 118: 1414.
252. Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: The populationbased Canadian Multicentre Osteoporosis Study (CaMoS) . Osteoporos Int 2014; 25: 1473-81.
253. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008; 135: 825-37.
254. de Sweit M,Ward PD, Fidler J, et al. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 1983; 90: 1129-34.
255. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-9.
256. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89: 3236-42.
257. Wiens M, Etminan M, Gill SS, et al. Effects of antihypertensive drug treatments on fracture outcomes: A meta-analysis of observational studies. J Intern Med 2006; 260: 350-62.
258. Butt DA, Mamdani M, Austin PC, et al. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 2013; 24: 2649-57.
259. Rejnmark L, Vestergaard P, Hickendorff L, et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: Results from a randomized controlled study with bumetenide. J Bone Miner Res 2006; 21: 163-70.